Average Co-Inventor Count = 6.14
ph-index = 5
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Bristol-myers Squibb Compnay (9 from 3,681 patents)
2. Astrazeneca Ab (1 from 1,500 patents)
3. Acadia Pharmaceuticals Inc. (1 from 92 patents)
11 patents:
1. 11452721 - Formulations of pimavanserin
2. 9198925 - Pharmaceutical formulations containing an SGLT2 inhibitor
3. 8716251 - Pharmaceutical formulations containing an SGLT2 inhibitor
4. 8361972 - Pharmaceutical formulations containing an SGLT2 inhibitor
5. 8221786 - Pharmaceutical formulations containing an SGLT2 inhibitor
6. 7851502 - Pharmaceutical formulations containing an SGLT2 inhibitor
7. 7659262 - Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di-amino acid salts, and mono- and di-amino acid ester salts
8. 7659261 - Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
9. 7524832 - Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts and mono-and di-amino acid ester salts
10. 6855702 - Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
11. 6670344 - Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts